PRECIGEN, INC. Line of Credit, Current
PRECIGEN, INC. (PGEN) had Line of Credit, Current of $0 as of 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current › Long-Term Debt, Current Maturities
us-gaap:LinesOfCreditCurrent · last filed 2021-03-01
- 2020-12-31: Line of Credit, Current $0.00.
- 2020-09-30: Line of Credit, Current $0.00.
- 2020-06-30: Line of Credit, Current $0.00.
- 2020-03-31: Line of Credit, Current $1.21M.
| Period end | Line of Credit, Current |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.21M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.92M 10-K · filed 2021-03-01 |
| 2019-09-30 | $569.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $387.00K 10-Q · filed 2019-08-09 |
| 2019-03-31 | $277.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $466.00K 10-K · filed 2020-03-02 |
| 2018-09-30 | $200.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $574.00K 10-Q · filed 2018-08-13 |
| 2018-03-31 | $321.00K 10-Q/A · filed 2018-08-13 |
| 2017-12-31 | $233.00K 10-K · filed 2019-03-01 |
| 2017-09-30 | $234.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $285.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $410.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $820.00K 10-K · filed 2018-03-01 |
| 2016-09-30 | $549.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $461.00K 10-Q · filed 2016-08-09 |
| 2016-03-31 | $536.00K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $561.00K 10-K · filed 2017-03-01 |
| 2015-09-30 | $475.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $873.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $621.00K 10-Q · filed 2015-05-11 |
| 2014-12-31 | $2.27M 10-K · filed 2016-02-29 |
| 2014-09-30 | $556.00K 10-Q · filed 2014-11-13 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |